477 related articles for article (PubMed ID: 26546252)
21. CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer.
Sun H; Wang C; Hao M; Sun R; Wang Y; Liu T; Cong X; Liu Y
Hum Pathol; 2016 Apr; 50():101-8. PubMed ID: 26997443
[TBL] [Abstract][Full Text] [Related]
22. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
23. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
24. MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.
Li X; Ji Y; Han G; Li X; Fan Z; Li Y; Zhong Y; Cao J; Zhao J; Zhang M; Wen J; Goscinski MA; Nesland JM; Suo Z
BMC Cancer; 2016 Nov; 16(1):894. PubMed ID: 27852261
[TBL] [Abstract][Full Text] [Related]
25. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
26. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
27. Positive nin one binding protein expression predicts poor outcome in prostate cancer.
Chen J; Wang J; Cui X; Liu Y; Yin L; Li Y; Chen L; Xu D; Gao Y
Mol Med Rep; 2015 Apr; 11(4):2671-6. PubMed ID: 25503472
[TBL] [Abstract][Full Text] [Related]
28. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
29. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
31. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma.
Ok Atılgan A; Özdemir BH; Akçay EY; Ataol Demirkan Ö; Tekindal MA; Özkardeş H
Pathol Res Pract; 2016 Feb; 212(2):83-92. PubMed ID: 26608417
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy.
Ren GF; Tang L; Yang AQ; Jiang WW; Huang YM
Histol Histopathol; 2014 Apr; 29(4):535-42. PubMed ID: 24222185
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.
Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y
Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477
[TBL] [Abstract][Full Text] [Related]
34. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
[TBL] [Abstract][Full Text] [Related]
35. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
36. miR-150 is a factor of survival in prostate cancer patients.
Dezhong L; Xiaoyi Z; Xianlian L; Hongyan Z; Guohua Z; Bo S; Shenglei Z; Lian Z
J BUON; 2015; 20(1):173-9. PubMed ID: 25778313
[TBL] [Abstract][Full Text] [Related]
37. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
[TBL] [Abstract][Full Text] [Related]
39. Low LKB1 Expression Results in Unfavorable Prognosis in Prostate Cancer Patients.
Lu J; Sun P; Sun B; Wang C
Med Sci Monit; 2015 Nov; 21():3722-7. PubMed ID: 26616116
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
